Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...
Srikala Sridhar, MD, MSc, FRCPC, outlines phase 2 data on avelumab in patients with locally advanced or metastatic penile cancer. The study included a total of 23 patients with a median age of 59 ...
Nivolumab significantly improves DFS, OS, and DSS in high-risk muscle-invasive urothelial carcinoma, especially in patients with PD-L1 expression ≥1%. The study's 5-year follow-up confirms nivolumab's ...
Andrew W. Hahn, MD, details phase 2 efficacy findings on lenvatinib plus everolimus vs cabozantinib in patients with metastatic ccRCC. Data from the phase 2 LenCabo trial (NCT05012371) showed that ...
The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...
Atezolizumab plus BCG did not improve EFS compared to BCG alone in high-risk NMIBC patients. No significant differences in EFS or RFS were observed between the combination and monotherapy arms. The ...
Aleece Fosnight, MSPAS, PA-C, highlights that although urinary leakage is common, it is not normal—and effective treatment options exist. In this interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback